ABVX ABIVAX Société Anonyme

84.12USD76.70 EUR · EPA+0.07%Mkt Cap: 7.31B USDP/E: —

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.…

Institutional holders11 on file

Key Statistics

Company
Market Cap7.31B USD
Enterprise Value6.22B USD
Revenue (TTM)5.12M USD
Gross Profit5.12M USD
Net Income (TTM)-368.64M USD
Revenue/Share0.07 USD
Last Price84.12 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees98
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0012333284
Valuation
P/E (Trailing)—
P/E (Forward)-26.27
PEG—
EV/EBITDA-19.46
EV/Revenue1215.28
P/S1427.14
P/B16.58
EPS (TTM)-5.71 USD
EPS (Forward)-3.18 USD
52W Range
66.3021% of range152.46
52W High152.46 USD
52W Low66.30 USD
Profitability
Gross Margin100.00%
Oper. Margin-6270.37%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-73.84%
ROA-57.52%
ROIC—
ROCE-47.20%
Growth
Revenue Growth-6.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-176.73M USD
CapEx (TTM)155.75K USD
FCF Margin-2697.05%
FCF Yield-1.89%
Net Debt-440.00M USD
Net Debt/EBITDA1.38
Net Debt/FCF—
Balance Sheet
Debt/Equity0.00
Current Ratio5.96
Quick Ratio5.79
Book Value/Sh5.03 USD
Cash/Share5.53 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)144.47 USD
Upside (mean)+71.7%
Target Range76.78 USD – 197.42 USD
76.78+71.7% to mean197.42
# Analysts7
Ownership
Shares Out.87.54M
Float70.84M
Insiders4.51%
Institutions53.01%
Technical
SMA 5090.71 (-7.3%)
SMA 200107.17 (-21.5%)
Beta-0.33
S&P 52W Chg12.00%
Avg Vol (30d)93.70K
Avg Vol (10d)130.35K
Technical Indicators
RSI (14)43.1
MACD-1.4541
MACD Signal-1.4282
MACD Hist.-0.0259
BB Upper91.35 USD
BB Middle86.47 USD
BB Lower81.59 USD
BB Width11.29%
ATR (14)3.936 USD
Vol Ratio (20d)0.73x

About ABIVAX (EPA: ABVX)

›

ABIVAX (EPA: ABVX) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 98 employees.

The shares were at 76.70 EUR on 19 November 2026, down 25.2% over 52 weeks. Its 52-week range is 60.45 EUR to 139.00 EUR: the price is 44.8% below the high and 26.9% above the low.

Its market capitalisation is 6.66B EUR.

ABIVAX reports return on equity of -73.8% and revenue down 6.8% year over year.

It holds more cash than debt, a net cash position of 401.17M EUR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 7 analysts cover the stock, with an average rating of Buy; their mean price target of 131.72 EUR is 71.7% above the current price. The next earnings report is expected on 22 March 2027.